SynthesisFrontiers in immunology2024

Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis.

Shibo Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.